Creating a new identity for a company creating a new treatment
Argonaut Therapeutics was founded on pioneering research from the University of Oxford, UK. Its a precision therapeutics company that was established to develop epigenetically-acting drugs which target abnormal arginine methylation in cancer. Argonaut strives to develop a new class of precision cancer medicines, that will revolutionise the way that disease is detected and treated.
They asked Phase Two to create a new brand and website for their company, for use going forward for a variety of print and digital applications. The identity was devised to represent a series of images that they provided.
STATIONERY. POWERPOINT PRESENTATIONS. CONSULTANCY AGREEMENTS. WEBSITE